TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29108664

Group type: EXPERIMENTAL
Intervention: 7 days sodium nitrate ingestion (∼8 mmol/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (NaCl solution)
Number of subjects: 20
Study: 26545726

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 22
Study: 24362589

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 186
Study: 22733310

Group type: EXPERIMENTAL
Intervention: Auditory feedback of movement trajectory error
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visual feedback of movement trajectory error
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Auditory feedback of error with trapezoid reference trajectory
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visual feedback of error with trapezoid reference trajectory
Number of subjects: 20
Study: 20513863

Group type: EXPERIMENTAL
Intervention: Catecholamine and indoleamine depletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18191734

Group type: EXPERIMENTAL
Intervention: RGEA
Number of subjects: 172

Group type: COMPARATOR
Intervention: SVG
Number of subjects: 172
Study: 16416150

Group type: EXPERIMENTAL
Intervention: Diurnal normobaric hypoxia (8 hours per day for 3 consecutive days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diurnal normobaric hypoxia
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (normoxic air for 8 hours per day for 3 consecutive days)
Number of subjects: 11
Study: 12827347

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 39
Study: 10832515

Group type: EXPERIMENTAL
Intervention: Conversation-based process tracing method using spoken answers and think aloud instructions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active Information Search (AIS) technique (as a basis for the method).
Number of subjects: 0
Study: 9086688

Group type: EXPERIMENTAL
Intervention: Random-effects regression models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional ANOVA models
Number of subjects: 0
Study: 8227449

Group type: EXPERIMENTAL
Intervention: AmF + SnF mouthwash (0.025% fluoride)
Number of subjects: 79

Group type: COMPARATOR
Intervention: NaF mouthwash (0.05% fluoride)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 3762014

Group type: COMPARATOR
Intervention: L-penbutolol (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-penbutolol (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31306465

Group type: EXPERIMENTAL
Intervention: Telephone administered brief HIV risk reduction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28184431

Group type: EXPERIMENTAL
Intervention: Nintedanib in combination with pemetrexed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-pemetrexed
Number of subjects: 0
Study: 25657183

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1733
Study: 23904191

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (SMART™)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Free combination of inhaled corticosteroid (ICS) + long‐acting β2‐agonist (LABA) and as‐needed short‐acting β2‐agonist (SABA)
Number of subjects: 482
Study: 21508090

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (100 μg/d)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (4000 μg/wk)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 μg/d)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (4000 μg/d)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: MTHFR genotype (TT vs CC)
Number of subjects: 932
Study: 19540137

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Carotid artery stenting (CAS)
Number of subjects: 5000
Study: 16282699

Group type: EXPERIMENTAL
Intervention: Pamidronate (125 mg) + oral calcium (500 mg/day) for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral calcium (500 mg/day) for 3 months
Number of subjects: 44
Study: 15520997

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 117
Study: 11287080

Group type: EXPERIMENTAL
Intervention: Pivagabine (900 mg, twice a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9209770

Group type: EXPERIMENTAL
Intervention: Group II (headache sufferers)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Group I (non-headache subjects)
Number of subjects: 53
Study: 8490077

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 0
Study: 3447933

Group type: EXPERIMENTAL
Intervention: RO 13-6438 (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RO 13-6438 (20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RO 13-6438 (30 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RO 13-6438 (all doses)
Number of subjects: 6
Study: 30854903

Group type: EXPERIMENTAL
Intervention: 4-week physical activity intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Stress-management counseling intervention
Number of subjects: 66
Study: 31025658

Group type: EXPERIMENTAL
Intervention: Endosonography-Guided Fine-Needle Aspiration (EUS-FNA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Key-Hole Biopsy (KHB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EUS-FNA and KHB (combined results)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EUS-FNA and KHB (mitotic activity)
Number of subjects: 46
Study: 30226494

Group type: EXPERIMENTAL
Intervention: Fast-track intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional attention
Number of subjects: 60
Study: 27665225

Group type: EXPERIMENTAL
Intervention: CD133+ stem cell therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24643340

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (both types)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Mediterranean diet groups
Number of subjects: 522
Study: 22610121

Group type: EXPERIMENTAL
Intervention: NIM (Nerve Integrity Monitor Pulse II)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Neurosign (Neurosign 1040 - 4 Channel EMG)
Number of subjects: 880
Study: 20825743

Group type: EXPERIMENTAL
Intervention: Insulin and Metformin Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18556906

Group type: EXPERIMENTAL
Intervention: Specifically matched coloured filters
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Placebo group with filters in a colour complementary to the individual's optimal colour
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group who received no intervention
Number of subjects: 49
Study: 16020407

Group type: EXPERIMENTAL
Intervention: Soy protein 15 g/d
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Soy protein 25 g/d
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Soy protein (both dosages)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 117
Study: 12501950

Group type: EXPERIMENTAL
Intervention: Dynamic standing (voluntary activation of lower leg muscles in able-bodied)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Stationary standing (FES-induced activation of lower leg muscles in spinal cord-injured)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Stationary standing
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dynamic standing
Number of subjects: 29
Study: 10360490

Group type: COMPARATOR
Intervention: Non-encrypted transmission
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 56-bit encryption
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 128-bit encryption
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 128-bit encryption with password
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: T1 connection
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dial-up modem connection
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy
Number of subjects: 14
Study: 8566673

Group type: EXPERIMENTAL
Intervention: Metronidazole 250mg plus Amoxicillin 500mg T.I.D for 10 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 1785002

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (resection only)
Number of subjects: 60
Study: 7010651

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation therapy (700 rads X 2)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 248
Study: 30727962

Group type: COMPARATOR
Intervention: Experimental Group-8 (EG8)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Experimental Group-4 (EG4)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 132
Study: 30157822

Group type: EXPERIMENTAL
Intervention: ProGlider file (PG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PathFile (PF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: K-file (KF)
Number of subjects: 60
Study: 25421236

Group type: EXPERIMENTAL
Intervention: Conventional Peanuts (CVP)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: High-Oleic Peanuts (HOP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control Biscuit (CT)
Number of subjects: 65
Study: 24447296

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1 μg.kg(‐1)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1.5 μg.kg(‐1)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 2 μg.kg(‐1)
Number of subjects: 213
Study: 22915643

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (20 mg/kg/d)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 21067805

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin daily
Number of subjects: 12064

Group type: COMPARATOR
Intervention: 20 mg simvastatin daily
Number of subjects: 12064
Study: 17922743

Group type: EXPERIMENTAL
Intervention: Hemoscan and Crit‐Line combination
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BVM and Crit‐Line combination
Number of subjects: 14

Group type: COMPARATOR
Intervention: Crit‐Line
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hemoscan
Number of subjects: 14

Group type: COMPARATOR
Intervention: BVM
Number of subjects: 14

Group type: COMPARATOR
Intervention: DeltaRBV from all devices
Number of subjects: 14
Study: 15951873

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (for 12 weeks)
Number of subjects: 32
Study: 12465197

Group type: EXPERIMENTAL
Intervention: Thermal bath
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional tub bath
Number of subjects: 15
Study: 10068580

Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous interleukin-2 (7.5 million IU twice a day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low-dose subcutaneous interleukin-2 (1.5 million IU twice a day)
Number of subjects: 49
Study: 7478680

Group type: EXPERIMENTAL
Intervention: Morphine solution taken at 4-hourly intervals for 7 days under direct nursing supervision
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Morphine solution
Number of subjects: 26
Study: 2343159

Group type: EXPERIMENTAL
Intervention: Message about losses without follow-up or gains with follow-up
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Exploratory analyses
Number of subjects: 116
Study: 7443365

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Muscular relaxation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biofeedback and relaxation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Minimal treatment control
Number of subjects: 40
Study: 31170627

Group type: EXPERIMENTAL
Intervention: Web-based acute pain management education program (400 min duration, 8 modules, 29 topics)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study: 28030716

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 4644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4644
Study: 26340807

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 36
Study: 23582742

Group type: EXPERIMENTAL
Intervention: EGFR TKIs (gefitinib, erlotinib, afatinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance-associated protein signature (RAPS)
Number of subjects: 0
Study: 21317645

Group type: EXPERIMENTAL
Intervention: Self-debriefing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Instructor debriefing
Number of subjects: 50
Study: 19139332

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 418

Group type: COMPARATOR
Intervention: Verteporfin PDT
Number of subjects: 418
Study: 17209188

Group type: EXPERIMENTAL
Intervention: Iron supplement (100 mg Fe/d as ferrous gluconate)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15182139

Group type: EXPERIMENTAL
Intervention: Foreign-born adolescents
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Medication taking behavior
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Living with both parents
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Sexual intercourse
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Speaking mostly or only English with parents
Number of subjects: 766
Study: 15857737

Group type: EXPERIMENTAL
Intervention: Palliative care intervention
Number of subjects: 224
Study: 10348714

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Tinzaparin (4,500 anti‐Factor IU Xa)
Number of subjects: 499
Study: 8739025

Group type: EXPERIMENTAL
Intervention: Tepoxalin (35 to 300 mg)
Number of subjects: 0
Study: 1764497

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/day), enalapril (5-20 mg/day), and hydrochlorothiazide (12.5-25 mg/day) as necessary.
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo (matching placebos)
Number of subjects: 3000
Study: 7123111

Group type: EXPERIMENTAL
Intervention: Five-year multifactorial intervention
Number of subjects: 5000
Study: 31638491

Group type: EXPERIMENTAL
Intervention: Quadratic support vector machine model for predicting ventilation maps
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Model-predicted ventilation defect percentage (VDP)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Model-predicted VDP
Number of subjects: 95
Study: 27753650

Group type: EXPERIMENTAL
Intervention: Pregabalin CR (82.5 to 660 mg/d)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study: 25541333

Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every other week for 24 weeks, then open-label adalimumab for up to 5 years
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 311
Study: 24285582

Group type: EXPERIMENTAL
Intervention: Extended-release (ER) niacin
Number of subjects: 12
Study: 22555264

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention delivered in 3 modules through nurse-led face-to-face counseling, computer-based education, and written teaching materials
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study: 19532100

Group type: EXPERIMENTAL
Intervention: Indapamide and ACE-inhibitor (if needed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE-inhibitor and angiotensin receptor blocker therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics, ACE-inhibitors, or angiotensin receptor blockers (if ACE-inhibitor intolerant)
Number of subjects: 0
Study: 17431603

Group type: EXPERIMENTAL
Intervention: 2 mg tadalafil
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 15462235

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 11354304

Group type: EXPERIMENTAL
Intervention: Prosorba treatment
Number of subjects: 3
Study: 9702141

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program to increase fruit and vegetable consumption
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both intervention and control participants
Number of subjects: 16
Study: 7746027

Group type: EXPERIMENTAL
Intervention: Limptar tablets (1 tablet containing 215.5 mg quinine and 167.2 mg theophylline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Limptar N tablets (1 tablet containing 165.75 mg quinine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chininum dihydrochloricum Buchler solution for injection (infusion of 163.3 mg quinine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Euphyllin 0.48 (short infusion of 168.6 mg theophylline)
Number of subjects: 12
Study: 30095601

Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Latanoprost/dorzolamide combination
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dorzolamide monotherapy
Number of subjects: 37
Study: 26708938

Group type: EXPERIMENTAL
Intervention: 10 billion heat‐killed Lactobacillus paracasei MCC1849 cells (LP group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo jelly without lactobacilli (placebo group)
Number of subjects: 42
Study: 26514192

Group type: EXPERIMENTAL
Intervention: Alteplase 0.9 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg
Number of subjects: 30
Study: 23102686

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 20860592

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with low-level laser therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonsurgical treatment alone (Control)
Number of subjects: 24
Study: 18082233

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 96
Study: 16649887

Group type: EXPERIMENTAL
Intervention: Exercise training (8-week outpatient exercise program)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 84
Study: 14569829

Group type: EXPERIMENTAL
Intervention: Sitting position during transcranial Doppler (TCD) examination
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Supine position during transcranial Doppler (TCD) examination
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison of both positions (sitting and supine)
Number of subjects: 34
Study: 10858678

Group type: EXPERIMENTAL
Intervention: Cough test
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tap test
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Trendelenberg test
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Perthes' test
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hand-held Doppler assessment
Number of subjects: 44
Study: 9351762

Group type: EXPERIMENTAL
Intervention: Pamphlet on triple-marker screening
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control pamphlet on daily activities during pregnancy
Number of subjects: 197
Study: 8458315

Group type: EXPERIMENTAL
Intervention: High energy supplement (3.31 MJ daily) for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole at the beginning of supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard health service care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High energy supplement
Number of subjects: 0
Study: 3739582

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 30
Study: 30227884

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional Exercise (CON) group
Number of subjects: 10
Study: 26572887

Group type: EXPERIMENTAL
Intervention: CT scanogram with 10% of the standard dose of ionizing radiation
Number of subjects: 10

Group type: COMPARATOR
Intervention: CT scanogram with 90% of the standard dose of ionizing radiation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison of native and repaired femurs using both doses
Number of subjects: 10
Study: 24807320

Group type: EXPERIMENTAL
Intervention: Collaborative depression management (n=102)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care (n=103)
Number of subjects: 205
Study: 22436082

Group type: EXPERIMENTAL
Intervention: Stepped-care program (N = 93)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Usual care (N = 92)
Number of subjects: 185
Study: 20439201

Group type: EXPERIMENTAL
Intervention: Heiney‐Adams Recruitment Framework (H‐ARF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health Insurance Portability and Accountability Act waivers
Number of subjects: 0
Study: 18662214

Group type: EXPERIMENTAL
Intervention: Multidisciplinary fall-prevention program
Number of subjects: 333

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 333